Enteral Lipid Supplementation and Bronchoplumonary Dysplasia of Premature Infants
Recruiting
Phase 4
Interventional Study
Bronchopulmonary Dysplasia (BPD)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 24 Weeks – 29 Weeks
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 74 (estimated)
- Sponsor
- Aristotle University Of Thessaloniki · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The Impact of Omega-3 (DHA - Docosahexaenoic Acid) and Omega-6 (ARA - Arachidonic Acid) Supplementation on the Development of Bronchopulmonary Dysplasia in Extremely and Very Preterm Infants (24-29 weeks of gestational age).
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Infants born at Papageorgiou Hospital in Neonatology Department and NICU of Aristotle University of Thessaloniki with GA equal to or less than 29 weeks are eligible to participate in the study.
Exclusion Criteria:
Congenital malformations, chromosomal abnormalities or critical…
Contacts
Maria Lithoxopoulou, MD, PhD, MBA, Ass. Prof.
+30 6932883161
mlithoxopoulou@yahoo.com, lithoxopoulou@auth.gr
CONTACT